News

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served as Chairman since 2020, will continue to serve as a member of the Board of Directors.

“We are delighted to welcome Dr. Williams as Chairman of our Board of Directors,” said David Marek, Chief Executive Officer of ReAlta. “His exceptional track record in building successful biopharmaceutical companies and expertise in drug development will be invaluable as ReAlta advances its clinical programs.”

“I would like to welcome Rusty to ReAlta at this exciting time in the company’s evolution,” said Buzz Heidt, member of ReAlta’s Board of Directors. “Rusty brings a wealth of leadership experience and insight to ReAlta, and I am eager to work with him as our incoming Board Chairman.”

“On behalf of the entire Board,” said Mr. Marek, “I wish to extend our sincerest gratitude to Buzz Heidt for over four years of Board service to ReAlta. Buzz’s collaborative partnership in the boardroom and strong leadership has positioned ReAlta for long-term success and Rusty and I look forward to his continued contributions as a Board member.”

“ReAlta is taking an innovative approach to address inflammation – the key driver of diseases across a wide spectrum of therapeutic areas. The unique ability of ReAlta’s dual-targeting EPICC peptides to address the earliest stages of the inflammatory cascade holds promise for treating inflammatory diseases successfully in ways existing therapies have been unable to,” said Dr. Williams. “I look forward to working closely with the Board Directors and management team to help realize the full potential of ReAlta’s technology to benefit patients with severe inflammatory diseases who currently have limited therapeutic options.”

Learn more here. 

Recent News

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …